The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 21, 2021
Filed:
Mar. 19, 2021
Applicant:
Nanocopoeia, Llc, New Brighton, MN (US);
Inventors:
Christian F. Wertz, Saint Louis Park, MN (US);
Tzehaw Chen, Saint Louis Park, MN (US);
Assignee:
Nanocopoeia, LLC, New Brighton, MN (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 9/00 (2006.01); A61K 9/10 (2006.01); A61K 31/341 (2006.01); A61K 31/4164 (2006.01); A61K 31/426 (2006.01); A61K 31/4439 (2006.01); A61K 47/32 (2006.01); A61K 47/14 (2017.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 9/0053 (2013.01); A61K 9/10 (2013.01); A61K 31/341 (2013.01); A61K 31/4164 (2013.01); A61K 31/426 (2013.01); A61K 31/4439 (2013.01); A61K 47/14 (2013.01); A61K 47/32 (2013.01);
Abstract
Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, orinfection.